Tagged with Acino

Middle Eastern Sovereign Wealth Funds Continue Pharma Investment Push

UAE Middle Eastern Sovereign Wealth Funds Continue Pharma Investment Push

UAE Sovereign wealth funds (SWFs) in the Gulf Cooperation Council (GCC) countries are increasingly investing in healthcare and the life sciences to reinforce their local industries and pursue the region’s economic diversification goals. Following the Saudi fund PIF’s launch of CDMO Lifera and Qatar’s QIA biotech investments, the UAE fund ADQ…

LatAm Pharma Roundup: Acino’s M8 Acquisition; Neuraxpharm’s Regional Expansion; AstraZeneca #1 in Mexico

LatAm LatAm Pharma Roundup: Acino’s M8 Acquisition; Neuraxpharm’s Regional Expansion; AstraZeneca #1 in Mexico

LatAm A roundup of some of the latest news from Latin American pharma, including Acino’s acquisition of M8 Pharmaceuticals; AstraZeneca’s growth in Mexico; Neuraxpharm’s expansion into Brazil and Mexico, and Columbia’s decision to issue a compulsory license for GSK/ViiV’s HIV treatment. Colombia set to issue a compulsory license for an…

Are Emerging Markets Back on Pharma’s Priority List?

Middle East & Africa Are Emerging Markets Back on Pharma’s Priority List?

Middle East & Africa As profit margins in established markets decreased, “pharmerging markets” became the new El Dorado for pharma and medtech companies in the 2010s. Many put in big investments only to discover that the volatility of these geographies often meant that the expected returns did not materialise. However, especially post-COVID, emerging markets…

Interview: Eugene Zaika – General Director Ukraine & CIS, Acino Pharma Start

Ukraine Interview: Eugene Zaika – General Director Ukraine & CIS, Acino Pharma Start

Ukraine Eugene Zaika, general director Ukraine and CIS of Pharma Start, a company acquired in October 2015 by Swiss-headquartered Acino Group and one of the leading players in Ukraine, provides insights into the group’s countercyclical investments in Ukraine, while Pharma Start’s ongoing successes prove that the risk taken is actually paying…

Interview: Kalle Känd – CEO, Acino, Switzerland

Switzerland Interview: Kalle Känd – CEO, Acino, Switzerland

Switzerland Managing volatility – the CEO of Acino, a Swiss pharmaceutical player, elaborates on the company’s unique strategy based on its significant expertise in volatile and uncertain key markets within their regions. Most of your career has been spent with mid-cap and big pharmaceutical companies. Three years ago, you decided to…

Other Topics

India

M&A

European Biotech

Cell & Gene Therapy

R&D Section Page